In my clinical practice I use FDG-PET for the following • • • • • 1- Staging 2- Therapeutic monitoring 3- Staging and therapeutic monitoring 4- I do not use FDG-PET; no access 5- I do not use FDG-PET; not cost effective “PET scans to image pharmacodynamic effects of vemurafenib” Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosure Information • I have the following financial relationships to disclose –Research support from: Pfizer, Millennium & Novartis Talk Outline • • • • FDG-PET response as a clinical tool in oncogene addiction – lessons from gastrointestinal stromal tumors (GIST). Responses on FDG-PET in patients treated with the BRAF inhibitor vemurafenib. Clinical and biological implications. FDG-PET as an early marker of response in patients with rare BRAF mutations. Could inhibition of glucose metabolism be important in response to BRAF inhibitors? p210Bcr-Abl CML GIST Oncogene Addiction Mut EGFR APML FDG-PET to assess response- Re-Evaluating the Conventional Treatment Paradigm GIST Before Imatinib 24 hours after starting Imatinib The Limitations of Structural Imaging 6 months after commencing imatinib Monitoring response to imatinib in GIST 1.0 0.9 0.8 PET responders n=13 0.7 0.6 Survival 0.5 p=0.001 0.4 0.3 PET non-responders n=8 0.2 0.1 0.0 0 100 200 300 400 500 600 700 Time (Days) Adapted from Stroobants et al, EJC, 2003 Talk Outline • • • • FDG-PET response as a clinical tool in oncogene addiction – lessons from gastrointestinal stromal tumors (GIST). Responses on FDG-PET in patients treated with the BRAF inhibitor vemurafenib. Clinical and biological implications. FDG-PET as an early marker of response in patients with rare BRAF mutations. Could inhibition of glucose metabolism be important in response to BRAF inhibitors Vemurafenib: a novel, small molecule inhibitor Selectivity for BRAFV600E in vitro and in vivo Selective for BRAFV600E kinase among 70 kinases screened Selective in cellular assays BRAF IC50 (nM) V600E 10–100 100–1000 1000–10000 WT Phospho-ERK IC50 (nM) A375 COLO829 COLO205 20 10 30 SW620 SKMEL2 >40,000 14,000 Dose dependent regression of V600E tumors Kinase domain binding Bollag et al , Nature, 2010 Bollag et al , Nature, 2010 CT Response- Phase 1 PLX06/02 Study Flaherty et al, NEJM, NEJM. 2010 Progression-free survival Progression-free survival (%) (30 Dec 2010, final pre-planned analysis at IA) 100 Hazard Ratio 0.26 90 (95% CI; 0.20 - 0.33) Log-rank P<0.0001 Vemurafenib (N=275) 80 70 Dacarbazine (N=274) 60 50 40 30 Median 5.3 mos Median 1.6 mos 20 10 0 0 1 2 3 4 5 274 275 213 268 7 8 9 3 4 0 3 10 11 12 Months No. of patients in follow up Dacarbazine Vemurafenib 6 85 211 48 122 28 105 16 50 10 35 6 16 McArthur et al, ESMO, 2011 Heterogeneity of ERK phosphorylation at progression 300 300 250 250 200 200 150 100 150 100 50 50 0 0 Baseline • pMEK1/2 cytoplasmic H-Score H-Score H-Score pERK1/2 cytoplasmic H-Score Day 15 PD Baseline Day 15 Recovery of ERK and MEK phosphorylation at disease progression was observed in some but not all patients McArthur ASCO, 2011 PD Patterns of Progression Baseline Response Progression Design of Clinical Study FDG-PET FDG-PET Procedure CT Day -21 1 Screening 15 CT CT 29 57 Vemurafenib FDG-PET Response Baseline Day 15 Kim, MD Anderson FDG-PET Response McArthur….Hicks, J Clin Oncol, 2012 Response Assessment -quantitative analyses PLX4032 ≥320mg Controls (n=4) bid (n=27) p Mean±SD Mean±SD Drug Exposure day 15 µM.hr 1683±153 69±16 0.0007 Change Target Lesions SUVmax (%) 80±17 8±19 <0.0001 Change Whole Body Lesions % Injected Dose(%) 84±15 1±41 <0.0001 Metabolic Disease Volume 816±423 ml (range) (7-6945) 597±1012 (16-2113) Response Assessment -summary PLX4032 ≥320mg bid Controls (n=27) (n=4) Overall Assessment of FDG-response (N, %) Complete Metabolic Response 3 (11%) Partial Metabolic 100% of patients with BRAF V600E41(89%) melanoma Response achieved an FDG-PET response No Response 0 1 0 3 2 (7%) 0 PR 21(78%) 0 SD 3 (11%) 0 Overall Assessment of CR response An RECIST (N, %) of precision example medicine McArthur….Hicks, J Clin Oncol, 2012 Homogeneity of Molecular Response A B McArthur….Hicks, J Clin Oncol, 2012 Conclusions • FDG-PET is a useful marker of early biological response to a vemurafenib with 100% of patients achieving partial or complete metabolic response. • FDG-PET responses were obtained in patients with high volumes of disease. Conclusions • Limited heterogeneity in FDG-PET response was found between lesions in individual pts suggesting minimal intrapatient molecular heterogeneity. • In this small patient cohort, very early FDG-PET response does not appear to be correlated with conventional clinical endpoints of PFS, Best Overall Response by RECIST, time to PR, or Duration of Response. Talk Outline • • • • FDG-PET response as a clinical tool in oncogene addiction – lessons from gastrointestinal stromal tumors (GIST). Responses on FDG-PET in patients treated with the BRAF inhibitor vemurafenib. Clinical and biological implications. FDG-PET as an early marker of response in patients with rare BRAF mutations. Could inhibition of glucose metabolism be important in response to BRAF inhibitors? BRAF K601E treated with the MEK-inhibitor trametinib A represents 1-2% of all BRAF mutations in melanoma K601E Day 0 B Day 17 BRAF T599 ins I V601 treated with the vemurafenib A Day 0 B Day 18 BRAF L597R treated with the vemurafenib A Day 0 B Day 14 Talk Outline • • • • FDG-PET response as a clinical tool in oncogene addiction – lessons from gastrointestinal stromal tumors (GIST). Responses on FDG-PET in patients treated with the BRAF inhibitor vemurafenib. Clinical and biological implications. FDG-PET as an early marker of response in patients with rare BRAF mutations. Could inhibition of glucose metabolism be important in response to BRAF inhibitors? Could inhibition of glucose metabolism be a driver of response? Baseline Day 15 Kim, MD Anderson Could inhibition of glucose metabolism be a driver of response? A Day 0 B Day 15 McArthur….Hicks, J Clin Oncol, 2012 Conclusions • • Mechanistic preclinical studies and correlations with reactivation of the MEK/ERK pathway suggest FDGPET is pharmacodynamic marker activity of MEK/ERK. Inhibition of glycolytic metabolism with siRNAs phenocopies the effects of vemurafenib on cell viability, suggesting inhibition of glycolytic metabolism maybe one component of the anti-tumor activity of BRAF inhibitors Acknowledgements Tiffany Parmenter PET-imaging Keith Flaherty Rod Hicks colleagues Antoni Ribas Jason Callahan Study Coordinators Paul Chapman Fergal Kelleher Patients & their Keith Nolop Alex Dobrovic families Jeff Sosman Cliff Meldrum Kevin Kim Igor Puzanov Joe Grippo Richard Lee Gideon Bollag